Clinical Data

Regenxbio’s Duchenne gene therapy clears phase 3 hurdle

Pharmaphorum

Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.

Gene Therapy Platform

Read full story

pharminent May 14, 2026 (Last updated: May 14, 2026)

Pharmaphorum

Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche’s Elevidys.

Gene Therapy Platform

Read full story

Related Stories

BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival

Novo says high-dose Wegovy can cause 28% weight loss

Pulsesight reports positive phase 1 data for PST611 in dry AMD

You May Have Missed

Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism

With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

Biotech leaders pitch Pazdur as next FDA chief

Degron adds $40M to series A, supporting immunology plans for molecular glue platform